Of these miR-1, miR-17, and miR-146a were previously reported to be upregulated in MS patients in PBMCs (miR-146a) (34–36), in CD4+ T cells (miR-1, miR-17) (36) or EAE-susceptible rats (miR-146a, miR-1) (37), implying an immunomodulatory effect of these miRNAs in MS. The gene discussed is CD4; the disease is myeloid sarcoma.